Items where authors include "Ludolph, A."

Article

Van Damme, P. orcid.org/0000-0002-4010-2357, Al‐Chalabi, A. orcid.org/0000-0002-4924-7712, Andersen, P.M. et al. (17 more authors) (2024) European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). European Journal of Neurology. ISSN 1351-5101

Opie-Martin, S., Iacoangeli, A., Topp, S.D. et al. (46 more authors) (2022) The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration. Nature Communications, 13 (1). 6901. ISSN 2041-1723

Al-Chalabi, A., Shaw, P. orcid.org/0000-0002-8925-2567, Leigh, P.N. et al. (6 more authors) (2019) Oral levosimendan in amyotrophic lateral sclerosis : a phase II multicentre, randomised, double-blind, placebo-controlled trial. Journal of Neurology, Neurosurgery & Psychiatry, 90 (10). pp. 1165-1170. ISSN 0022-3050

Al-Chalabi, A. orcid.org/0000-0002-4924-7712, Andersen, P.M., Chandran, S. et al. (38 more authors) (2017) July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18 (7-8). pp. 471-474. ISSN 2167-8421

Forde, N.J., Kanaan, A.S., Widomska, J. et al. (39 more authors) (2016) TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome. Frontiers in Neuroscience, 10. 384.

Agosta, F., Al-Chalabi, A., Filippi, M. et al. (9 more authors) (2014) The El Escorial criteria: Strengths and weaknesses. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 16 (1-2). pp. 1-7. ISSN 2167-8421

Turner, M.R., Bowser, R., Bruijn, L. et al. (11 more authors) (2013) Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14 (Sup1). pp. 19-32. ISSN 2167-8421